search
Back to results

Evaluation of Integrated Versus Parallel Connection for Renal Replacement Therapy in ECMO Patients (EPIC-ECMO)

Primary Purpose

Venoarterial Extracorporeal Membrane Oxygenation, Renal Replacement Therapy, Acute Kidney Injury

Status
Not yet recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Parallel connection
Integrated connection
Sponsored by
Hospices Civils de Lyon
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Venoarterial Extracorporeal Membrane Oxygenation focused on measuring VA-ECMO, RRT, connection, integrated, parallel, hemofilter

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients between 18 and 75 years of age Patient on VA-ECMO who requires the initiation of continuous RRT during VA-ECMO treatment Patient with a foreseeable length of stay in intensive care greater than 24 hours Exclusion Criteria: Patient who does not have a vascular capital allowing for the insertion of a new dialysis catheter to administer RRT and therefore cannot be randomized to the parallel connection group Pregnant, parturient, or breastfeeding women Patient deprived of liberty by a judicial or administrative decision Patient under psychiatric care Patient subject to a legal protection measure (guardianship, curators) Patient not affiliated to a social security system Patient participating in another interventional research study

Sites / Locations

  • CHU de Bordeaux, GH Sud, Service d'anesthésie-réanimation cardiovasculaire, Hôpital cardiologique
  • CHU de Clermont Ferrand, Pôle de médecine péri-opératoire/Chirurgie cardiaque, Hôpital Gabriel Montpied
  • CHU de Grenoble, Service de réanimation cardiovasculaire et thoracique, Pôle anesthésie réanimation, Hôpital Nord
  • Hospices Civils de Lyon, Service d'Anesthésie-Réanimation cardiovasculaire, Hôpital Louis Pradel
  • CHU de Montpellier, Département d'anesthésie-réanimation, Pôle Cœur-poumons, Hôpital Arnaud de Villeneuve
  • APHP, Institut de Cardiologie, Service d'anesthésie-réanimation cardiovasculaire, Hôpital de la Pitié-Salpêtrière
  • APHP, Institut de cardiologie, Service de Médecine Intensive Réanimation, Hôpital Pitié-Salpêtrière
  • CHU de Saint Etienne, Hôpital Bellevue, Service de Réanimation polyvalente et soins intensifs post-opératoires

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

VA-ECMO patients with parallel connection

VA-ECMO patients with integrated connection

Arm Description

Patients undergoing VA ECMO with indication for concomitant RRT, assigned to parallel connection group.

Patients undergoing VA ECMO with indication for concomitant RRT, assigned to integrated connection group.

Outcomes

Primary Outcome Measures

Hemofilter change rate
To assess whether integrated RRT connection in VA-ECMO patients results in a non-inferior hemofilter change rate compared to the parallel connection. The hemofilter change rate is defined as the number of hemofilter replacements observed during the period between the start and the end of the RRT session, normalized by the duration of the session.

Secondary Outcome Measures

Proportion of early hemofilter thromboses
To assess if the integrated RRT connection is associated with a lower proportion of early hemofilter thromboses compared to the parallel connection: number of early hemofilter thromboses normalized by the number of hemofilters used. "Early" is defined as < 24 hours of use.
Proportion of hemofilter thromboses
To assess if the integrated RRT connection is associated with a lower proportion of hemofilter thromboses compared to the parallel connection: number of hemofilter thromboses normalized by the number of hemofilters used.
Down-time
To compare the integrated RRT connection to the parallel connection in terms of duration of non-purification periods in relation to the total duration RRT.
Renal function according to KDIGO stage
To assess renal function at hospital discharge or at day 60 after admission.
Number of infectious complications
To assess whether the integrated RRT connection reduces the number of infectious complications associated with the use of an additional vascular access. The infection will be defined as catheter-related in case of documented bacteraemia with positive blood cultures with differential time to positivity or positive catheter culture with the same microorganism.
Number of bleeding complications
To assess whether the integrated RRT connection reduces bleeding complications associated with the use of an additional vascular access. The occurrence of a bleeding syndrome is defined as a bleeding requiring transfusion with collection of the number of red blood cells transfused or requiring an invasive procedure (surgery, embolization), and defined or not as related to dialysis catheter placement or RRT connection to VA-ECMO.
Proportion of ECMO circuit thromboses
To assess whether the integrated RRT connection does not expose the ECMO circuit to a higher probability of thrombosis The occurrence of thrombosis on the ECMO circuit is defined as a thrombus on any part of the ECMO circuit requiring a change in the circuit or oxygenator, or on the oxygenator resulting in a deleterious effect on oxygenation, or resulting in significant fibrinolysis
Number of hemolysis
To assess whether the integrated RRT connection does not expose to a higher probability of hemolysis. The occurrence of intravascular hemolysis is defined as the occurrence of significant hemolytic anemia.
Number of air embolism
To assess whether the integrated RRT connection does not expose the patient to a higher probability of air embolism. The occurrence of an air embolism is defined as an embolic event with clinical impact of any kind, This occurence is related or not to the use of the dialysis catheter or the connection of the RRT to the VA-ECMO circuit.
Number of days spent in intensive care unit
To assess whether the integrated RRT connection modifies the intensive care unit length of stay
Death
30-day mortality

Full Information

First Posted
August 31, 2023
Last Updated
September 14, 2023
Sponsor
Hospices Civils de Lyon
search

1. Study Identification

Unique Protocol Identification Number
NCT06038162
Brief Title
Evaluation of Integrated Versus Parallel Connection for Renal Replacement Therapy in ECMO Patients
Acronym
EPIC-ECMO
Official Title
Evaluation of Integrated Versus Parallel Continuous Renal Replacement Therapy Connection in ECMO Patients: a Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
October 2023 (Anticipated)
Primary Completion Date
September 2025 (Anticipated)
Study Completion Date
September 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hospices Civils de Lyon

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Extracorporeal membrane oxygenation (ECMO) is an extra-corporeal assistance used in case of respiratory or circulatory failure. In case of circulatory failure, ECMO is in the veno-arterial configuration (VA-ECMO). VA-ECMO patients are at high risk of developing acute kidney injury (AKI) and renal replacement therapy (RRT) may be needed in 50% of ECMO patients. Although the administration of RRT in ECMO patients has major implications, no specific recommendations are currently available. The 2020 Kidney Disease: Improving Global Outcomes (KDIGO) international conference identified the evaluation of RRT in these ECMO patients as a research priority. In 2023, the two main configurations used to administer RRT in ECMO patients are an independent delivery on a separate vascular access (parallel connection) or an integration of the RRT machine directly into the ECMO circuit (integrated connection). The integrated connection may reduce infectious and bleeding complications associated with the use of a second vascular access. However, it can expose the hemofilter and circuit to excessive positive pressures that can trigger pressure alarms in the RRT machine and expose the patient to a theoretical risk of air embolism or hemolysis. Furthermore, there is currently no robust data comparing the hemofilter lifespan with the parallel or with the integrated connection, although the filter lifespan is a crucial parameter to assess the quality of the RRT delivery in the ICU. The investigators recently performed a survey of practices in this context of ECMO patients. The investigators found that both strategies (parallel and integrated connection) are widely used and can be seen as common patient care. The hypothesis tested in this study is the following: when RRT is integrated to the ECMO circuit, the hemofilter lifespan is non inferior to the one when RRT is delivered on a separate vascular access. Only VA-ECMO patients will be enrolled in this trial.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Venoarterial Extracorporeal Membrane Oxygenation, Renal Replacement Therapy, Acute Kidney Injury
Keywords
VA-ECMO, RRT, connection, integrated, parallel, hemofilter

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
158 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
VA-ECMO patients with parallel connection
Arm Type
Active Comparator
Arm Description
Patients undergoing VA ECMO with indication for concomitant RRT, assigned to parallel connection group.
Arm Title
VA-ECMO patients with integrated connection
Arm Type
Active Comparator
Arm Description
Patients undergoing VA ECMO with indication for concomitant RRT, assigned to integrated connection group.
Intervention Type
Procedure
Intervention Name(s)
Parallel connection
Intervention Description
The RRT machine is connected on a separate vascular access (dialysis catheter).
Intervention Type
Procedure
Intervention Name(s)
Integrated connection
Intervention Description
A connection of the RRT machine with the input and output lines directly on the ECMO circuit.
Primary Outcome Measure Information:
Title
Hemofilter change rate
Description
To assess whether integrated RRT connection in VA-ECMO patients results in a non-inferior hemofilter change rate compared to the parallel connection. The hemofilter change rate is defined as the number of hemofilter replacements observed during the period between the start and the end of the RRT session, normalized by the duration of the session.
Time Frame
Duration of RRT associated with VA-ECMO up to 60 days
Secondary Outcome Measure Information:
Title
Proportion of early hemofilter thromboses
Description
To assess if the integrated RRT connection is associated with a lower proportion of early hemofilter thromboses compared to the parallel connection: number of early hemofilter thromboses normalized by the number of hemofilters used. "Early" is defined as < 24 hours of use.
Time Frame
Duration of RRT associated with VA-ECMO up to 60 days
Title
Proportion of hemofilter thromboses
Description
To assess if the integrated RRT connection is associated with a lower proportion of hemofilter thromboses compared to the parallel connection: number of hemofilter thromboses normalized by the number of hemofilters used.
Time Frame
Duration of RRT associated with VA-ECMO up to 60 days
Title
Down-time
Description
To compare the integrated RRT connection to the parallel connection in terms of duration of non-purification periods in relation to the total duration RRT.
Time Frame
Duration of RRT associated with VA-ECMO up to 60 days
Title
Renal function according to KDIGO stage
Description
To assess renal function at hospital discharge or at day 60 after admission.
Time Frame
At hospital discharge up to 60 days after admission
Title
Number of infectious complications
Description
To assess whether the integrated RRT connection reduces the number of infectious complications associated with the use of an additional vascular access. The infection will be defined as catheter-related in case of documented bacteraemia with positive blood cultures with differential time to positivity or positive catheter culture with the same microorganism.
Time Frame
Duration of RRT associated with VA-ECMO up to 60 days
Title
Number of bleeding complications
Description
To assess whether the integrated RRT connection reduces bleeding complications associated with the use of an additional vascular access. The occurrence of a bleeding syndrome is defined as a bleeding requiring transfusion with collection of the number of red blood cells transfused or requiring an invasive procedure (surgery, embolization), and defined or not as related to dialysis catheter placement or RRT connection to VA-ECMO.
Time Frame
Duration of RRT associated with VA-ECMO up to 60 days
Title
Proportion of ECMO circuit thromboses
Description
To assess whether the integrated RRT connection does not expose the ECMO circuit to a higher probability of thrombosis The occurrence of thrombosis on the ECMO circuit is defined as a thrombus on any part of the ECMO circuit requiring a change in the circuit or oxygenator, or on the oxygenator resulting in a deleterious effect on oxygenation, or resulting in significant fibrinolysis
Time Frame
Duration of RRT associated with VA-ECMO up to 60 days
Title
Number of hemolysis
Description
To assess whether the integrated RRT connection does not expose to a higher probability of hemolysis. The occurrence of intravascular hemolysis is defined as the occurrence of significant hemolytic anemia.
Time Frame
Duration of RRT associated with VA-ECMO up to 60 days
Title
Number of air embolism
Description
To assess whether the integrated RRT connection does not expose the patient to a higher probability of air embolism. The occurrence of an air embolism is defined as an embolic event with clinical impact of any kind, This occurence is related or not to the use of the dialysis catheter or the connection of the RRT to the VA-ECMO circuit.
Time Frame
Duration of RRT associated with VA-ECMO up to 60 days
Title
Number of days spent in intensive care unit
Description
To assess whether the integrated RRT connection modifies the intensive care unit length of stay
Time Frame
Duration of RRT associated with VA-ECMO up to 60 days
Title
Death
Description
30-day mortality
Time Frame
At 30 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients between 18 and 75 years of age Patient on VA-ECMO who requires the initiation of continuous RRT during VA-ECMO treatment Patient with a foreseeable length of stay in intensive care greater than 24 hours Exclusion Criteria: Patient who does not have a vascular capital allowing for the insertion of a new dialysis catheter to administer RRT and therefore cannot be randomized to the parallel connection group Pregnant, parturient, or breastfeeding women Patient deprived of liberty by a judicial or administrative decision Patient under psychiatric care Patient subject to a legal protection measure (guardianship, curators) Patient not affiliated to a social security system Patient participating in another interventional research study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Frank BIDAR, MD
Phone
(33) 472 116 942
Email
frank.bidar@chu-lyon.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Thomas RIMMELE, Professor MD
Phone
(33) 472 111 327
Email
thomas.rimmele@chu-lyon.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Frank BIDAR, MD
Organizational Affiliation
Hospices Civils de Lyon
Official's Role
Study Chair
Facility Information:
Facility Name
CHU de Bordeaux, GH Sud, Service d'anesthésie-réanimation cardiovasculaire, Hôpital cardiologique
City
Bordeaux
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alexandre OUATTARA, Professor MD
Phone
(33) 557 656 866
Email
alexandre.ouattara@chu-bordeaux.fr
Facility Name
CHU de Clermont Ferrand, Pôle de médecine péri-opératoire/Chirurgie cardiaque, Hôpital Gabriel Montpied
City
Clermont-Ferrand
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vedat ELJEZI, Professor MD
Phone
(33) 473 751 590
Email
veljezi@chu-clermontferrand.fr
Facility Name
CHU de Grenoble, Service de réanimation cardiovasculaire et thoracique, Pôle anesthésie réanimation, Hôpital Nord
City
Grenoble
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Géraldine DESSERTAINE, MD
Phone
(33) 476 767 588
Email
Gdessertaine@chu-grenoble.fr
Facility Name
Hospices Civils de Lyon, Service d'Anesthésie-Réanimation cardiovasculaire, Hôpital Louis Pradel
City
Lyon
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jean-Luc FELLAHI, Professor MD
Phone
(33) 472 118 933
Email
Jean-luc.fellahi@chu-lyon.fr
Facility Name
CHU de Montpellier, Département d'anesthésie-réanimation, Pôle Cœur-poumons, Hôpital Arnaud de Villeneuve
City
Montpellier
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Philippe GAUDARD, MD
Phone
(33) 467 335 958
Email
p-gaudard@chu-montpellier.fr
Facility Name
APHP, Institut de Cardiologie, Service d'anesthésie-réanimation cardiovasculaire, Hôpital de la Pitié-Salpêtrière
City
Paris
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Adrien BOUGLE, MD
Phone
(33) 142 162 259
Email
Adrien.bougle@aphp.fr
Facility Name
APHP, Institut de cardiologie, Service de Médecine Intensive Réanimation, Hôpital Pitié-Salpêtrière
City
Paris
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Charles-Edouard LUYT, Professor MD
Phone
(33) 142 163 824
Email
Charles-edouard.luyt@aphp.fr
Facility Name
CHU de Saint Etienne, Hôpital Bellevue, Service de Réanimation polyvalente et soins intensifs post-opératoires
City
Saint-Étienne
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jérôme MOREL, Professor MD
Phone
(33) 477 828 329
Email
Jerome.morel@chu-st-etienne.fr

12. IPD Sharing Statement

Learn more about this trial

Evaluation of Integrated Versus Parallel Connection for Renal Replacement Therapy in ECMO Patients

We'll reach out to this number within 24 hrs